In the field of diabetes care, Lilly’s Humalog and Trulicity have been major revenue drivers. Eli Lilly and Company (NYSE:LLY ...

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The new lower prices apply to some doses of Zepbound provided in vials but not the autoinjector pens.

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced its full results and reiterated its earlier 2025 forecast. The company has ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Worldwide Trulicity revenue declined 25% ... in everything about Eli Lilly and Company. If you've got follow-up questions or things we didn't cover in enough detail today in the Q&A.

Eli Lilly And Co (NYSE:LLY ... Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.30 billion. GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91% ...